Several studies have found CD44 to have a role in impaired prognosis in many malignant tumors, such as hepatic carcinoma, lung carcinoma, breast carcinoma, melanoma, gastric carcinoma, and HNSCC. Here, CD44 is linked to breast carcinoma.